Filter Results:
(1,243)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
- 13 Feb 2006
- Research & Ideas
The Hidden Market for Babies
infertility: eggs, sperm, and wombs. Sometimes, these components are sold along with IVF treatment—when a couple purchases eggs, for example, they are subsequently used for an IVF procedure—but they are often provided by individual brokers. Then there are the View Details
- 06 Feb 2007
- First Look
First Look: February 6, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=806092 Endo Pharmaceuticals (A): From LBO to...? Harvard Business School Case 806-064 Endo Pharmaceuticals was formed in 1997 as a leveraged... View Details
Keywords: Martha Lagace
- 13 Jul 2020
- News
Locally Grown
pharmaceutical machinery sector. With the natural beauty of the Rocky Mountains as a backdrop for his career decision, Fenwick-Smith became increasingly interested in climate change and what the business community could do to make a... View Details
Keywords: April White
- 01 May 2007
- First Look
First Look: May 1, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=207113 Strategy in the 21st Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. Harvard Business School Case 707-509 The global View Details
Keywords: Sean Silverthorne
- 01 Dec 1996
- News
New Releases
a competitive factor. In a three-year study of pharmaceutical and biotechnology firms, Pisano shows that the development of distinctive and superior process technologies can lower costs, improve quality, and increase flexibility. He... View Details
- 15 Sep 2009
- First Look
First Look: September 15
http://www.nber.org/papers/w11503 Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era Author:Arthur A. Daemmrich Publication:History and Technology 23, no. 3 (2009): 237-256 Abstract This... View Details
Keywords: Martha Lagace
- 01 Sep 2011
- News
MBA 101: HBS Commencements Pass the Century Mark
pharmaceutical executive at the time of her diagnosis with multiple myeloma, an incurable, rare, and little-researched blood cancer, Giusti went on to found the Multiple Myeloma Research Foundation and the Multiple Myeloma Research... View Details
- 01 Mar 2007
- News
Pharma Suits a Farm Gal
GRAHAM: From rodeo to CEO. Amylin Pharmaceuticals CEO Ginger Graham (MBA ’86) had a good year in 2006, with Amylin stock up as much as 45 percent, with Byetta and Symlin, its two innovative diabetes drugs, performing well, and with the... View Details
- 01 Mar 2007
- News
In Brief
Q&A with Daniel Vasella. Initially regarded by critics as too inexperienced to lead a major pharmaceutical company, Daniel Vasella (PMD 57, 1989) has set a new standard for innovation as CEO of Novartis. The Winning Season. Last year, St.... View Details
- 06 Mar 2018
- News
A Voice for Diversity and Impact at Scale
its Pharmaceutical and Medical Products Practice in Europe, the Middle East, and Africa. And as a member of the global board of directors, she has spearheaded flagship research linking diversity to performance, championing the notion that... View Details
- Student-Profile
Olivia Zhao
pros and cons of a public system facing increased privatization. Research Olivia’s research hones in on the pharmaceutical industry and looking at the lifecycle of a drug. “It starts, of course, with research and development at huge drug... View Details
- 01 Jan 2004
- News
Donald P. Nielsen, MBA 1963
self-cleaning rat cages for psychology labs. Learning that pharmaceutical companies use large quantities of rats, they negotiated a deal with him and over the next few months also executed a roll-up strategy that eventually made them the... View Details
- 28 Mar 2023
- Blog Post
Novo Nordisk
learned details of how Novo Nordisk manufactures within its 1,200,000 square meter facility high-quality active pharmaceutical ingredients (APIs) that tackle not only diabetes but also hemophilia, growth disorders, and obesity. At their... View Details
- 01 Jan 2008
- News
Jeffrey R. Immelt, MBA 1982
protein biomarkers that have been identified as the precursor to Alzheimer’s disease. “There’s still no cure,” he observes, “but if you know that someone has the early signs of the disease and combine that with some of the new drugs the View Details
- May 2015
- Case
Transforming Alkermes into a Global Biopharmaceutical Company
By: C. Fritz Foley and Nicholas Haas
In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about how to finance the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT)—a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information... View Details
Keywords: Financing; Debt; Merger; CFO; Financial Management; Pharmaceutical Industry; Pharmaceutical Industry; United States; Europe
Foley, C. Fritz, and Nicholas Haas. "Transforming Alkermes into a Global Biopharmaceutical Company." Harvard Business School Case 215-079, May 2015.
- Article
Governments as Owners: State-Owned Multinational Companies
By: Alvaro Cuervo-Cazurra, Andrew Inkpen, Aldo Musacchio and Kannan Ramaswamy
The globalization of state-owned multinational companies (SOMNCs) has become an important phenomenon in international business (IB), yet it has received scant attention in the literature. We explain how the analysis of SOMNCs can help advance the literature by... View Details
Keywords: Multinational Corporation; State-owned Enterprises; State Capitalism; FDI; Internationalization; Government And Business; National Oil Companies; State Ownership; Multinational Firms and Management; Business Subsidiaries; Acquisition; Pharmaceutical Industry; Pharmaceutical Industry; China; India; Europe
Cuervo-Cazurra, Alvaro, Andrew Inkpen, Aldo Musacchio, and Kannan Ramaswamy. "Governments as Owners: State-Owned Multinational Companies." Special Issue on Governments as Owners: Globalizing State-Owned Enterprises edited by Alvaro Cuervo-Cazurra, Andrew Inkpen, Aldo Musacchio and Kannan Ramaswamy. Journal of International Business Studies 45, no. 8 (October–November 2014): 919–942.
- April 2011
- Teaching Note
Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)
By: Willy Shih and Sen Chai
Teaching Note for 611057. View Details
- November 2009 (Revised December 2009)
- Case
GTC Biotherapeutics: Developing Medicines in the Milk of Goats
By: Ray A. Goldberg and Sarah Morton
GTC is the first company in the animal world to receive FDA approval of a transgenic pharmaceutical. What are the implications for other firms in plants and animals and their opportunities to produce new medicines in an economical and safe fashion? View Details
Keywords: Health Care and Treatment; Animal-Based Agribusiness; Plant-Based Agribusiness; Science-Based Business; Medical Specialties; Product; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry; United States
Goldberg, Ray A., and Sarah Morton. "GTC Biotherapeutics: Developing Medicines in the Milk of Goats." Harvard Business School Case 910-403, November 2009. (Revised December 2009.)
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Pharmaceutical Industry; Pharmaceutical Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)